GC Corp. 4

What Happened
GC Corp., reported as a 10% owner of Artiva Biotherapeutics (ARTV), purchased a total of 1,432,291 shares on May 11, 2026. The filing shows two open-market/private purchases: 1,085,069 shares at $11.52 each ($12,499,995) and 347,222 shares at $11.52 each ($3,999,997), for a combined cash outlay of $16,499,992. These were purchases (P), which are generally seen as a bullish signal because the holder increased its stake.

Key Details

• Transaction date: 2026-05-11 (two purchases at the same price)
• Price: $11.52 per share for both lots
• Shares acquired: 1,085,069 and 347,222 — total 1,432,291 shares
• Total transaction value: $16,499,992 (~$16.5M)
• Filing date: 2026-05-28 — filing appears late (trade reported 17 days after the transactions; Form 4s are typically due within 2 business days)
• Shares owned after transaction: Not specified in the provided excerpt of the filing
• Footnotes: GC Corp. is a public Korean holdings company and parent of GC Cell Corporation; shares are held by GC Cell Corporation per the filing. The board members of GC Corp. are listed and are noted to share voting/investment power over these holdings but disclaim beneficial ownership except for any pecuniary interest.

Context

• This transaction was by a reported 10% institutional owner (GC Corp./GC Cell Corporation), not an individual executive; such purchases reflect institutional appetite rather than a company's officer/director signal.
• Two same-day purchases at the same price via open-market/private purchase simply increased the holder’s position — not an option exercise, grant, or gift.
• The late filing reduces the timeliness of this disclosure for investors and could be subject to SEC scrutiny or penalties for tardy reporting.